Better Health for All

Arbutus Biopharma's core business is entirely focused on developing a functional cure for chronic Hepatitis B (HBV), a disease affecting over 257 million people globally

and causing approximately 1.1 million annual deaths. Their lead therapeutic, imdusiran, has demonstrated functional cure rates of up to 50% in select patients and 25% overall in Phase 2a trials. However, the company has discontinued two other drug candidates, AB-161 and AB-452, due to preclinical safety findings including male reproductive toxicity and peripheral neurotoxicity in animal studies. The company discloses these preclinical safety findings and the discontinuation of the drug candidates. Arbutus is focused on R&D, with its entire business model centered on developing novel therapeutics for HBV. The company conducts animal studies under IACUC-approved protocols and clinical trials in compliance with the Declaration of Helsinki and ICH Good Clinical Practice. The company's website uses cookies and provides a privacy policy outlining their use. Arbutus is involved in patent litigation against Moderna over LNP patent infringement.

Fair Money & Economic Opportunity

Arbutus Biopharma Corporation is a biopharmaceutical company focused on developing therapies for chronic hepatitis B virus (HBV) infection.

Its core business activities do not involve lending, insuring, moving, or storing money for consumers. Therefore, all Key Performance Indicators (KPIs) related to financial services, such as customer lending, fee structures, financial inclusion initiatives, and financial literacy programs, are not applicable to the company's operations. The company does not offer consumer credit products, manage customer finance data, or operate as a regulated lender.

Fair Pay & Worker Respect

No specific, concrete data points were found for any of the KPIs under Fair Pay & Worker Respect. While CEO pay was mentioned,

the median employee compensation for the company was not provided, preventing calculation of the CEO to median pay ratio. Employee reviews from Glassdoor provided an average rating of 3.5 out of 5 stars and a 61% recommendation rate, but these are not direct 'employee-survey engagement / satisfaction index' scores on a 0-100 scale as required by the rubric. Furthermore, the company laid off 57% of its staff in Q1 2025, reducing its workforce to 19 employees, which is a significant event impacting worker respect, but the rubric does not provide a KPI to score this specific action.

Fair Trade & Ethical Sourcing

The provided article, a consulting agreement, explicitly states that it contains no data relevant to Arbutus Biopharma's fair trade and ethical sourcing practices, supply chain, or compliance with fair trade standards.

Therefore, no KPIs can be scored based on the available evidence.

Kind to Animals

ABUS.US conducts animal studies involving mice, rats, dogs, guinea pigs, and non-human primates (cynomolgus monkeys and rhesus macaques).

All animal-related procedures are performed at facilities accredited by AAALAC International, such as Genevant Sciences Corporation, Charles River Laboratories Ashland, and St. Louis University Medical School. These facilities adhere to the Canadian Council on Animal Care Guidelines, the USDA Animal Welfare Act, and the Guide for the Care and Use of Laboratory Animals (2011), with all protocols approved by local Institutional Animal Care and Use Committees (IACUC). The company uses some non-animal methods, including in vitro competitive binding studies, red blood cell hemolysis assays, and HBV cell-based systems, which primarily cover early-stage toxicity screens. Annually, the company uses between 10,000 and 15,000 animals in testing. The company's animal testing policy mandates adherence to regulatory guidelines and IACUC approval, but it does not prohibit all non-essential testing. There is no evidence of active public policy engagement or advocacy for higher animal welfare standards beyond compliance with existing regulations.

Planet-Friendly Business

No specific, concrete data points for Arbutus Biopharma Corporation's environmental performance were found across the provided articles. While the company has an SDG Transparency Score of 34.4 (Low)

and an ESG Risk Rating of 35.9 (High), ranking 632 out of 847 in Pharmaceuticals, these are overall assessments and do not provide the granular metrics required by the rubric for individual KPIs, such as total emissions, renewable energy usage, or waste diversion rates. Industry-wide data for the biotech and pharma sector was provided, but no specific metrics for Arbutus Biopharma Corporation were detailed.

Safe & Smart Tech

Arbutus Biopharma reported no material cybersecurity incidents or threats for 2024, and no specific incidents of unauthorized data use.

The company conducts internal and external audits, including annual penetration tests. New employees and contractors receive cybersecurity training upon onboarding and annually thereafter. The company states it maintains a robust cybersecurity program leveraging industry frameworks, including NIST, and no regulatory actions, violations, fines, or compliance issues were mentioned.

Zero Waste & Sustainable Products

The company implements several waste reduction initiatives, including recycling, repurposing materials, eliminating plastic waste, and donating unused consumables.

Regarding hazardous waste, the company is prohibited from causing or permitting hazardous materials to be brought upon, kept, used, stored, handled, treated, generated in or about, or released or disposed of from its premises in violation of applicable environmental requirements. It is also required to deliver an updated Hazardous Materials List to the Landlord at least once a year and provide Haz Mat Documents such as permits, approvals, and reports.